Tumor recurrence remains the major cause of management failure after surgical resection of
glioblastoma (GBM). Immunotherapy has the potential to effectively eradicate tumors and …

The development of chemoimmunotherapy with reduced systemic toxicity using local
formulations is an effective strategy for combating tumor recurrence. Herein, we reported a …

Immunotherapies have revolutionized intervention strategies for many primary cancers, but
have not improved the outcomes of glioblastoma multiforme (GBM), which remains one of …

Tumor recurrence remains the leading cause of treatment failure following surgical resection
of glioblastoma (GBM). M2-like tumor-associated macrophages (TAMs) infiltrating the tumor …

Infiltrative glioma growth makes surgical excision incomplete, and the residual tumor cells
proliferate rapidly. Residual glioma cells evade phagocytosis by macrophages through …

It is well known that glioma is currently the most malignant brain tumor. Because of the
existence of blood-brain barrier (BBB) and tumor cell heterogeneity, systemic chemotherapy …

Successful treatment of glioblastoma (GBM) is hampered by primary tumor recurrence after
surgical resection and poor prognosis, despite adjuvant radiotherapy and chemotherapy. In …

Glioblastoma, the most common malignant tumor of the central nervous system, readily
relapses after surgery. Based on the CD47-SIRPα axis, we designed and implanted a …

The efficacy of standard glioblastoma (GBM) treatments has been limited due to the highly
immunosuppressive tumor immune microenvironment, interpatient tumor heterogenicity and …

Immunotherapy has been used for cancer treatment, while it faces the common dilemmas of
low therapeutic efficacy and serious immunotoxicity. In this study, we report the construction …